| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
5 |
/ |
2017 |
|
|
|
| |
Data sporządzenia: |
2017-04-03 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
Regulatory Marketing Clearance to Sell Epidural and Intra-Articular Instruments and
Disposables in Australia
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, "the Company", "the Issuer"_,
today announced that it has been granted marketing clearance for its epidural and
intra-articular instruments and disposables in Australia.
Dynamic Pressure Sensing® _DPS_ capability in the CompuFlo® Epidural instrument provides
feedback that allows anesthesiologists to correctly identify the epidural space, which
has the potential to significantly reduce complications and malpractice compared to
conventional techniques. DPS technology is also incorporated into the CompuFlo® Intra-Articular
instrument to provide precise computerized drug injections into intra-articular joint
spaces in osteoarthritis patients. CompuFlo® Intra-Articular provides drug delivery
accuracy, reduces patient discomfort and prevents needle deflection.
The Board of Directors of Issuer is pleased to announce regulatory marketing clearance
to sell its epidural and intra-articular instruments and disposables in Australia.
Australia represents a sizable market for its technology with more than 300,000 live
births per year and approximately 1.8 million residents with osteoarthritis. The CompuFlo®
Epidural and Intra-Articular instruments provide new clinical tools to enhance the
safety and reduce pain associated with epidural and intra-articular procedures.
|
|
|
RB_ASO: Regulatory Marketing Clearance to Sell Epidural and Intra-Articular Instruments and
Disposables in Australia
